[1] SERAVALLE G, GRASSI G. Obesity and hypertension[J]. Pharmacol Res, 2017, 122:1-7. doi:  10.1016/j.phrs.2017.05.013
[2] ALPERT M A, OMRAN J, BOSTICK B P. Effects of obesity on cardiovascular hemodynamics, cardiac morphology, and ventricular function[J]. Curr Obes Rep, 2016, 5(4):424-434. doi:  10.1007/s13679-016-0235-6
[3] TWIG G, YANIV G, LEVINE H, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood[J]. N Engl J Med, 2016, 374(25):2430-2440. doi:  10.1056/NEJMoa1503840
[4] WOLFE B M, KVACH E, ECKEL R H. Treatment of obesity: weight loss and bariatric surgery[J]. Circ Res, 2016, 118(11):1844-1855. doi:  10.1161/CIRCRESAHA.116.307591
[5] BLÜHER M. Obesity: global epidemiology and pathogenesis[J]. Nat Rev Endocrinol, 2019, 15(5):288-298. doi:  10.1038/s41574-019-0176-8
[6] SQUADRITO F, ROTTURA M, IRRERA N, et al. Anti-obesity drug therapy in clinical practice: evidence of a poor prescriptive attitude[J]. Biomed Pharmacother, 2020, 128:110320. doi:  10.1016/j.biopha.2020.110320
[7] RUAN Y, XIANG K F, ZHANG H M, et al. Orosomucoid: a promising biomarker for the assessment of exercise-induced fatigue triggered by basic combat training[J]. BMC Sports Sci Med Rehabil, 2022, 14(1):100. doi:  10.1186/s13102-022-00490-6
[8] 徐栋平. 急性期蛋白ORM在缺血性脑卒中的保护作用及其机制研究[D]. 上海: 第二军医大学, 2018.
[9]

SUN Y, YANG Y L, QIN Z, et al. The acute-phase protein orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway[J]. Diabetes, 2016, 65(6):1630-1641. doi:  10.2337/db15-1193
[10]

KORT E, JOVINGE S. Drug repurposing: claiming the full benefit from drug development[J]. Curr Cardiol Rep, 2021, 23(6):62. doi:  10.1007/s11886-021-01484-5
[11]

QIU Y, SUN Y M, XU D Q, et al. Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue[J]. EBioMedicine, 2018, 37:344-355. doi:  10.1016/j.ebiom.2018.10.019